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The impact of dermatology consultations on antibiotic usage for suspected cases
of cellulitis presenting to outpatient internal medicine offices
R. Arakaki1, E. Woo2 and D. Kroshinsky2, 1Harvard Medical School, Boston, Massachusetts, USA
and 2Massachusetts General Hospital, Boston, Massachusetts, USA
There are many conditions that clinically mimic cellulitis. Dermatologist expertise in infectious
and inflammatory skin diseases facilitates confirmation of diagnosis or identification and proper
treatment of a clinical mimicker of cellulitis. Our study sought to determine if obtaining
dermatology consultations in the setting of primary-care offices could assist in diagnosis of
mimickers of cellulitis and therefore reduce the rate of antibiotic usage. The primary objective
was to measure the rate of antibiotic usage in patients with suspected cellulitis who received a
dermatology consultation versus those who received standard of care for cellulitis from their
primary-care physician. This was a randomized controlled study performed in the outpatient
internal medicine offices at Massachusetts General Hospital. The patient population of interest
included all adult patients over the age of 18 presenting to primary care with possible cellulitis as
determined by their primary-care physician. The intervention used was an on-site dermatology
consultation. The primary outcome measured was the rate of antibiotic usage. This study enrolled
a total of 25 patients, with 16 patients randomized to a dermatology consultation and 9 patients
randomized to receive the standard of care for cellulitis. Of the 16 patients randomized to a
dermatology consult, 3 patients received antibiotics and 13 did not. Of the 9 patients randomized
to the standard of care, all 9 received antibiotics. This study was terminated prior to reaching the
original enrollment target because interim analysis showed statistical significance. Fisher’s exact
test demonstrated a P-value of 0.0001. No adverse events occurred. In conclusion, this study was
notable for demonstrating that the rate of antibiotic usage in patients with suspected cellulitis can
be reduced by involving a dermatology consultation during a patient’s visit to primary-care
offices. We believe that the difference in antibiotic usage rates highlights the prevalence of
conditions that mimic cellulitis and the potential benefit of early involvement of dermatology in
the care of patients presenting with suspected cellulitis. As a result of this study, we have initiated
a similar project to assess the impact of dermatologic consultation on the hospital course of
patients who have been admitted for cellulitis.
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Treatment of refractory cutaneous dermatomyositis: an academic medical
center0s experience with intravenous immunoglobulin
Alisa N. Femia, A. Brooke Eastham, Christina Lam, Stephanie W. Liu, Henry B. Townsend,
Joseph F. Merola, Abrar A. Qureshi and Ruth Ann Vleugels, Brigham and Women’s Hospital,
Harvard Medical School, Boston, Massachusetts, USA
Dermatomyositis (DM) is a chronic inflammatory condition affecting both skin and muscle.
Treatment can be difficult, and cutaneous manifestations may be particularly refractory to
therapy. Antimalarials are considered first-line systemic agents, but are often insufficient, and
literature on skin-directed therapy is limited. Previous studies on intravenous immunoglobulin
(IVIG), including one small randomized-controlled trial, have evaluated patients treated primarily
for muscle disease, but no study has aimed to assess patients treated specifically for cutaneous
disease. Our goal was to investigate the role of IVIG initiated for cutaneous disease, particularly in
DM skin disease recalcitrant to systemic agents. We utilized the Research Patient Data Registry, a
centralized registry of the Partners Healthcare System, to identify all patients treated with IVIG
specifically for cutaneous DM. We reviewed the medical records of 11 patients prescribed IVIG
by a dermatologist, with the goal of improving cutaneous DM. Seven patients lacked clinical
muscle involvement. The usual dose of IVIG was 2 g kg1 over 2 consecutive days every 4 weeks,
and treatment duration ranged from 3 to 24 months. Clinical response (CR) was based on
improvement in skin disease as determined by clinicians, defined as no CR, partial CR (o75%),
marked CR (475%), or complete CR. Six patients had complete CR, 2 had marked CR, and 3 had
partial CR. Four patients had disease severity followed using the validated Cutaneous
Dermatomyositis Disease Area and Severity Index (CDASI). All patients improved within
1 month. All but one patient had cutaneous disease previously refractory to systemic medications
other than hydroxychloroquine, 7 of whom were refractory to multiple systemic agents. Six
patients were treated with oral corticosteroids prior to IVIG; all were able to taper or discontinue
corticosteroids following IVIG. In addition, all patients with skin-limited disease were able to
discontinue other immunosuppressive agents. Side effects were minimal, and consisted of
headaches in two patients. IVIG may be effective in treating cutaneous DM, including refractory,
skin-predominant DM, and may spare the need for immunosuppression. In our population,
response was rapid and side effects minimal. This is the first study to demonstrate the effect of
IVIG specifically as skin-directed therapy in patients with DM, including in patients lacking
clinical muscle involvement.
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Changing incidence trends of cutaneous lymphoma
K. Korgavkar1,2 and M.A. Weinstock1,2,3,4, 1Dermatoepidemiology Unit, VA Medical Center,
Providence, Rhode Island, USA; 2Department of Dermatology, Alpert Medical School of Brown
University, Providence, Rhode Island, USA; 3Department of Dermatology, Rhode Island Hospital,
Providence, Rhode Island, USA and 4Department of Epidemiology, Alpert Medical School of
Brown University, Providence, Rhode Island, USA
The reported incidences of cutaneous T-cell lymphoma (CTCL) and cutaneous B-cell lymphoma
(CBCL) have risen for more than 25 years. Improvement in detection by physicians and a real
increase in the number of cases have been suggested as the etiologies. We sought to measure
recent trends. Data for cutaneous lymphomas in the United States were acquired from 18
population-based cancer registries of the Surveillance, Epidemiology, and End Results (SEER)
Program of the National Cancer Institute for 2000–2009, and from the 9 original cancer registries
of the SEER program for 1973–2009. We used the 37-year data to measure long-term incidence
trends and the 10-year data to measure recent trends. Consistent with previously reported data,
incidence of CTCL (per million persons) increased steadily from 2.3 in 1973 to a maximal annual
average of 10.5 in the period 2000–2004. However, the incidence rate has remained unchanged
since then, with an annual average of 10.2 for 2005–2009. Incidence of CBCL (per million
persons) may show a leveling off trend also; it has steadily increased from 0.63 in 1973 to an
average annual rate of 3.66 for 2000–2004, and 3.76 for 2005–2009. In the past 15 years, CBCL
incidence has doubled in whites while remaining unchanged in blacks. However, in the most
recent period of 2005–2009, the increase in CBCL among whites was small. From 2000 to 2009, a
total of 9,538 cases of cutaneous lymphoma were identified. The overall age-adjusted incidence
was 11.9 per million persons. CTCL accounted for 73% of these (8.7 per million persons) while
CBCL accounted for 27% (3.2 per million persons). Consistent with previous report, incidence
was higher in men compared to women, with an incidence rate ratio (IRR) of 1.64 for CTCL and
1.64 also for CBCL. Incidence varied by race, with a black:white IRR of 1.28 in CTCL and 0.46 in
CBCL. The latter indicates a decrease from previously reported data. Cutaneous lymphoma
incidence has been increasing for decades. However, CTCL incidence has leveled off in recent
years. In CBCL, incidence continues to increase in whites, although it may be leveling off as well,
and it remains unchanged in blacks. The causes for these trends are not known.
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Association of discoid lupus with other clinical manifestations among patients
with systemic lupus erythematosus
J.F. Merola1,2, S.D. Prystowsky3, C. Iversen1, J.A. Gomez-Puerta1, T. Norton1, P. Tsao1,
E. Massarotti1, P. Schur1, B. Bermas1 and K.H. Costenbader1, 1Brigham and Women’s Hospital,
Harvard Medical School, Department of Medicine, Division of Rheumotology, Boston,
Massachusetts, USA; 2Brigham and Women’s Hospital, Harvard Medical School, Department
of Dermatology, Boston, Massachusetts, USA and 3New York University Medical Center,
Department of Dermatology, New York City, New York, USA
Prior studies suggest cutaneous discoid lupus (DLE) among patients with SLE may be a marker for
less severe disease, with low frequency of nephritis and end-stage renal disease (ESRD). These
studies have not confirmed DLE diagnosis by a dermatologist or assessed medication effects. The
objective of this study was to investigate associations between DLE and other specific SLE
manifestations in a large validated SLE cohort. Our SLE registry contains data on 5,030 patients
since 1970, involving rheumatologist confirmation of SLE by chart review, 44/11 of 1997 ACR
classification criteria for SLE,42 visits and43 months of follow-up, and documented year of SLE
diagnosis. Cases of DLE were confirmed by a dermatologist–rheumatologist review of
dermatology notes and supported by histopathology and images, when applicable. Data
collected included SLE manifestations, medications, and serologic data. Multivariable-adjusted
logistic regression analyses were used to test for associations between DLE and, individually, each
of the ACR SLE criteria and ESRD among SLE patients. Of the 1,043 SLE patients included, DLE
(n¼ 117) was significantly associated with the presence of photosensitivity, leukopenia, and anti-
Smith antibodies. DLE was inversely associated with both arthritis and pleuritis. We found no
significant associations between DLE and nephritis or ESRD. In conclusion, we found an
increased frequency of photosensitivity, leukopenia, and anti-Smith antibodies among SLE
patients with DLE and an inverse association of DLE with both pleuritis and arthritis. We did not
observe the inverse associations of DLE with anti-dsDNA antibodies, lupus nephritis, or ESRD
previously described in other studies. These findings have important implications for prognosis
among SLE patients with DLE.
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Comparison study of three pemphigus disease activity measurements: PDAI,
ABSIS, and PVDAI
Z. Rahbar, M. Daneshpazhooh, P. Hejazi, N. Aghazadeh and C. Chams-Davatchi, Autoimmune
Bullous Diseases Research Center, Tehran University for Medical Sciences, Tehran, Iran
The meta-analysis of the pemphigus trials was limited because of the inconsistencies in outcomes
measured in available evidences. Disease activity measurements are pivotal in clinical studies to
provide with interpretable results. Clinic-based measurements such as PDAI (Pemphigus Vulgaris
Area Index) developed by the International Pemphigus Committee, ABSIS (Autoimmune Bullous
Skin Disorder Intensity Score) used mostly in Europe, and PVDAI (Pemphigus Vulgaris Disease
Activity Index) applied in Iran are validated to assess pemphigus disease extent. Also, antibody
titer as a surrogate measure is known to correlate mostly with disease activity in pemphigus. The
objective of this study was to compare these measurements in a large number of patients
confirmed with pemphigus. Hundred patients with confirmed diagnosis of PV and clinical
pemphigus lesions who signed the informed consent were enrolled. They were evaluated by
PDAI, PVDAI, and ABSIS and the serum was stored on the same day, to measure anti-dsg 1 and 3
using ELISA. Three dermatologists evaluated all patients through measurements while blinded to
others’ results and provided with random forms. The data computation and analysis was
performed using SPSS 20. The mean age of patients was 43.3 years, with a female:male ratio of
1.27. Inter-rater reliability studies between the three raters showed a Spearman’s rho coefficient of
0.95 for PDAI, 0.88 for ABSIS, and 0.82 for PVDAI. Correlation with PDAI as an international
consensus score was 0.82 for PVDAI and 0.66 for ABSIS. Correlation between anti-dsg1 and the
measurements was 0.65, 0.32, and 0.52 for PDAI, ABSIS, and PVDAI, respectively. Anti-dsg 3
level was most correlated with oral involvement of ABSIS (0.50). The regression model predicted
limb involvement and the presence of Nikolsky sign for higher titers of Dsg1 (Po0.01). The male
gender, older age, upper airways involvement of PDAI, and subjective discomfort of ABSIS
seemed to result in higher titers of anti-dsg3. The median time to score was 2.8, 1.9, and
1.1minutes for PDAI, ABSIS, and PVDAI, respectively. In conclusion, PDAI is a highly reliable
measurement, especially for skin activity, as it calculates the visible lesions in a systematized
order. It does not need much experience to assess the Nikolsky sign, types of lesions, or rule of
nine, which would be sources of variability. Although it takes more time and seems more difficult
in the beginning, most raters were satisfied with this measurement.
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Intertriginous pustular psoriasiform response to anti-tumor necrosis factor-a
therapy
Ryan E. Sells, Joseph F. Merola, Alisa Femia, Ruth Ann Vleuges and Abrar Qureshi, Brigham and
Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Tumor necrosis factor antagonists are increasingly utilized for the treatment of multiple
inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, psoriasis,
and psoriatic arthritis. A growing body of literature over the past 10 years has documented
paradoxical development or worsening of psoriasis in some patients treated with anti-tumor
necrosis factor-a (TNF-a) inhibitors. This adverse reaction typically follows months to years of
treatment, but may develop even after treatment has been discontinued abruptly without
transitioning onto another immunosuppressive regimen. These psoriatic eruptions are typically
characterized by scaly erythematous plaques involving the scalp, trunk, or groin. Alternatively, a
palmoplantar pustulosis has also been commonly described, mainly on the palms and soles. In
this study, we report a new finding in a series of patients who developed INtertriginous
PsoriAsiform reactions with Sterile Satellite pustulEs (INPASSE) involving the axilla, submammary
areas, crural folds, and perianal areas following TNF-a antagonist therapy, including with
infliximab, etanercept, and adalimumab. The patients were on anti-TNF therapy for the following
diseases: Crohn’s disease, psoriatic arthritis, and autoimmune uveitis. Some cases were associated
with marked scalp inflammation, which was notable for ‘‘boggy’’ induration reminiscent of
dissecting cellulitis. Pustules were found to be sterile on bacterial culture. These pustular
reactions were resistant to therapy, requiring the addition of adjuvant therapies, such as
minocycline, acitretin, and methotrexate, in combination with topical-directed therapy. Further
efforts should be directed at classifying this population of patients and also characterizing the role
of TNF-a inhibitors in provoking these pustular eruptions.
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